Search company, investor...
Hydra Biosciences company logo

Hydra Biosciences

hydrabiosciences.com

Founded Year

2001

Stage

Asset Sale | AssetsPurchased

Total Raised

$95.18M

About Hydra Biosciences

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Mass. that develops drugs to treat pain, inflammation, anxiety and other diseases using its expertise in novel ion channels. Hydra Biosciences' proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs.

Headquarters Location

45 Moulton Street

Cambridge, Massachusetts, 02138,

United States

617-494-5230

Missing: Hydra Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Hydra Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Hydra Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hydra Biosciences is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Hydra Biosciences Patents

Hydra Biosciences has filed 1 patent.

The 3 most popular patent topics include:

  • Ion channels
  • Membrane biology
  • Electrophysiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/13/2019

11/1/2022

Ion channels, Transcription factors, Clusters of differentiation, Kidney diseases, G protein coupled receptors

Grant

Application Date

2/13/2019

Grant Date

11/1/2022

Title

Related Topics

Ion channels, Transcription factors, Clusters of differentiation, Kidney diseases, G protein coupled receptors

Status

Grant

Latest Hydra Biosciences News

Hydra Biosciences Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13112018 Prices from USD $250

Dec 26, 2018

21:40 EST 25 Dec 2018 | BioPortfolio Reports Summary Hydra Biosciences Inc Hydra is a biopharmaceutical company that formulates new drugs to treat pain , inflammation, anxiety and other diseases employing its expertise in new ion channels. The company's pipeline candidate HX100 is used to treat diabetic neuropathy and allergic asthma. Its pipeline also includes Lead Op TRPV3 for the treatment of dermatological disorders, and HittoLead TRPV4 for treating pulmonary fibrosis. It also offers drugs for renal diseases, central nervous system CNS, and pulmonary diseases. The company partners with Boehringer Ingelheim to develop TRPC4/5 targeting renal diseases and CNS disorders. Its proprietary Transient Receptor Potential TRP platform and integrated pharmacology and chemistry infrastructure allow Hydra to discover and develop novel drug compounds. Hydra is headquartered in Cambridge, Massachusetts, the US. Hydra Biosciences Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Hydra Biosciences Frequently Asked Questions (FAQ)

  • When was Hydra Biosciences founded?

    Hydra Biosciences was founded in 2001.

  • Where is Hydra Biosciences's headquarters?

    Hydra Biosciences's headquarters is located at 45 Moulton Street, Cambridge.

  • What is Hydra Biosciences's latest funding round?

    Hydra Biosciences's latest funding round is Asset Sale.

  • How much did Hydra Biosciences raise?

    Hydra Biosciences raised a total of $95.18M.

  • Who are the investors of Hydra Biosciences?

    Investors of Hydra Biosciences include Eli Lilly and Company, Boehringer Ingelheim, Advanced Technology Ventures, Abingworth, BioVentures Investors and 10 more.

  • Who are Hydra Biosciences's competitors?

    Competitors of Hydra Biosciences include Evotec SE, Arena Pharmaceuticals, Integral Molecular, Icagen, Acetylon Pharmaceuticals and 13 more.

Compare Hydra Biosciences to Competitors

M
MuriGen

MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

J
JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

G
GRAPP

Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute (www.vai.org) and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

Integral Molecular Logo
Integral Molecular

Integral Molecular develops technologies to enable the discovery and development of drugs that target integral membrane proteins, which are involved directly or indirectly in most major diseases, and comprise nearly half of all existing drug targets, including G protein-coupled receptors (GPCRs) and ion channels.

A
Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.